Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

被引:0
作者
Michael Roggendorf [1 ]
机构
[1] Institute of Virology,University Hospital Essen
关键词
Hepatitis B virus; Programmed death-1; Programmed death ligands; Hepatitis; Hepatocellular carcinoma;
D O I
暂无
中图分类号
R575.1 [肝炎]; R735.7 [肝肿瘤];
学科分类号
1002 ; 100201 ; 100214 ;
摘要
AIM: To investigate the expression of programmed death (PD)-1,PD ligand 1 (PD-L1) and PD-L2 in liver tissues in the context of chronic hepatitis and hepatocellular carcinoma (HCC).METHODS: Liver biopsies and HCC specimens from patients were collected and histologically examined.The expression of PD-1,PD-L1,and PD-L2 in biopsy specimens of chronic hepatitis and HCC specimens was evaluated by immunohistochemical staining.The association between the expression level of PD-1,PD-L1,and PD-L2 and clinical and pathological variables was analyzed statistically.RESULTS: Expression of PD-1 was found in liverinfiltrating lymphocytes.In contrast,PD-L1 and PD-L2 were expressed in non-parenchyma liver cells and tumor cells.The expression of PD-L1 was significantly correlated with hepatitis B virus infection (1.42 ± 1.165 vs 0.50 ± 0.756,P = 0.047) and with the stage of HCC (7.50 ± 2.121 vs 1.75 ± 1.500 vs 3.00 ± 0.001,P = 0.018).PD-1 and PD-Ls were significantly up-regulated in HCC specimens (1.40 ± 1.536 vs 5.71 ± 4.051,P = 0.000;1.05 ± 1.099 vs 4.29 ± 3.885,P = 0.004;1.80 ± 1.473 vs 3.81 ± 3.400,P = 0.020).CONCLUSION: PD-L1 may contribute to negative regulation of the immune response in chronic hepatitis B.PD-1 and PD-Ls may play a role in immune evasion of tumors.
引用
收藏
页码:3322 / 3329
页数:8
相关论文
共 50 条
  • [1] Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma
    Wang, Bao-Ju
    Bao, Jun-Jie
    Wang, Jun-Zhong
    Wang, Yang
    Jiang, Min
    Xing, Ming-You
    Zhang, Wan-Guang
    Qi, Jun-Ying
    Roggendorf, Michael
    Lu, Meng-Ji
    Yang, Dong-Liang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (28) : 3322 - 3329
  • [2] Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
    Ma, Li-Jie
    Feng, Fei-Ling
    Dong, Liang-Qing
    Zhang, Zhao
    Duan, Meng
    Liu, Long-Zi
    Shi, Jie-Yi
    Yang, Liu-Xiao
    Wang, Zhi-Chao
    Zhang, Shu
    Ding, Zhen-Bin
    Ke, Ai-Wu
    Cao, Ya
    Zhang, Xiao-Ming
    Zhou, Jian
    Fan, Jia
    Wang, Xiao-Ying
    Gao, Qiang
    THERANOSTICS, 2018, 8 (20): : 5690 - 5702
  • [3] PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma
    Curran, Colleen S.
    Sharon, Elad
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 428 - 432
  • [4] Expression and clinical significance of PD-1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD-1 monoclonal antibody
    Li, Ziwei
    Li, Bin
    Peng, Dan
    Xing, Haiyan
    Wang, Guanying
    Li, Pan
    Wang, Jiming
    Ye, George
    Chen, Jianhong
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (06) : 2079 - 2092
  • [5] Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients
    Tan, Zhiwu
    Chiu, Mei Sum
    Yang, Xinxiang
    Yue, Ming
    Cheung, Tan To
    Zhou, Dongyan
    Wang, Yuewen
    Chan, Anthony Wing-Hung
    Yan, Chi Wing
    Kwan, Ka Yi
    Wong, Yik Chun
    Li, Xin
    Zhou, Jingying
    To, Ka Fai
    Zhu, Jiye
    Lo, Chung Mau
    Cheng, Alfred Sze-Lok
    Chan, Stephen Lam
    Liu, Li
    Song, You-Qiang
    Man, Kwan
    Chen, Zhiwei
    GUT, 2023, 72 (08) : 1568 - 1580
  • [6] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
    Kim, Chang Gon
    Kim, Chan
    Yoon, Sang Eun
    Kim, Kyung Hwan
    Choi, Seong Jin
    Kang, Beodeul
    Kim, Hye Ryun
    Park, Su-Hyung
    Shin, Eui-Cheol
    Kim, Yeun-Yoon
    Kim, Dae Jung
    Chung, Hyun Cheol
    Chon, Hong Jae
    Choi, Hye Jin
    Lim, Ho Yeong
    JOURNAL OF HEPATOLOGY, 2021, 74 (02) : 350 - 359
  • [8] Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor
    Guo, Yusheng
    Ren, Yanqiao
    Wu, Feihong
    Dong, Xiangjun
    Zheng, Chuansheng
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [9] Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor
    Guo, Yusheng
    Ren, Yanqiao
    Wu, Feihong
    Dong, Xiangjun
    Zheng, Chuansheng
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [10] PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
    Xu, Yongkang
    Fu, Shumin
    Shang, Kai
    Zeng, Jiayu
    Mao, Ye
    FRONTIERS IN ONCOLOGY, 2022, 12